USB vs ZYME · P/E 12, rev $28.66B vs rev $76.3M
U.S. Bancorp (USB) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
USB currently screens at market cap $74.68B and trailing P/E 11.9. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the USB and ZYME stock pages for the full models.
Not investment advice.